A HIGHLY ACCURATE
UNDERSTANDING OF PHRAMA
ASSET RISK & RETURN
The range and scope of product-level information available across Evaluate Omnium transforms strategic portfolio decisions.
Combine risk and return data metrics and landscapes for quick, efficient, side-by-side comparisons based on consistent, proven methodologies. Customise metrics and visualisations, and easily integrate these into existing workflows.
Combine product-specific PTRS and predicted peak sales analytics to provide a single metric for forecasting the commercial potential of different pharma assets across all phases of clinical development. Predict ROI at product indication, product and company level.
Leverage NPV by indication that covers 8x more NPV models for R&D programmes that aren't usually covered by existing consensus forecasts. Improve your understanding of product value drivers.
Identify which in-house and competitor drugs are most likely to reach the market successfully. Proprietary algorithms, powered by machine learning, enable cross-comparison across products and indications to better balance portfolio risk across a range of attributes:
Predict when key development milestones will occur for US and EU pipeline programs - enabling comparison of progress against competitors and highlighting products with first in class potential. Includes: time-in-phase predictions, recruitment timeline benchmarks, filing and launch date predictions, and market entry order predictions.
Track critical product lifecycle and company events, such as trial initiations, regulatory decisions and financial results.
Assess likely costs across the development cycle with the industry s first comprehensive clinical trial costing model, which applies real-world data to over 50,000 trials. Includes: estimated, product-level trial costs for past and current clinical trials; future R&D cost predictions by product and phase; and industry benchmarks by indication.
Track clinical trials from three key industry sources (CT.gov, EudraCT and Japanese trials); fully understand company development plans and pipelines; identify historical and future trial trends; understand competition in the trial landscape; and monitor trial life cycle by indication.
Predict the future patient enrolment needed to successfully complete clinical development, alongside historical benchmarks by phase and indication. Access aggregated and standardised trial outcomes for indications and products, updated daily.
Predict the value of key R&D assets with an independent
and balanced view, including:
Assess market impact and inform product launch planning.
Rank or compare indications to better focus portfolio investments on areas with the greatest impact to patients, using a tool that quantifies and standardises the degree of unmet need within an indication.
Identify the current market access position for products launched in the US, with benchmarks that help assess the implications and opportunities for products in development.
Streamline research and inform pricing strategies.
Evaluate’s methodology is well-documented and
transparent, which lets me understand where their
numbers are coming from. As a result, I can speak about
their data with conviction. ”
Evaluate Omnium is one of the most robust offerings
for commercial sales data, probability of success and
time-in-phase data in a single platform. We recently
completed an R&D forecasting project and couldn’t have
done the work without it. ”
Evaluate Omnium is the key piece of our Evaluate
subscription. The highly granular PTRS benchmarks
allow us to use specific numbers in work and not depend
on broad benchmarks from other source. We believe
that Evaluate is the best provider of this data. ”
I have really come to understand the benefit of
using Evaluate Omnium over competing products.
The amount of information they make available is
amazing. Omnium is outstanding. ”